Targeted drug shows promise for Hard-to-Treat cancers
NCT ID NCT04439136
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tested the drug afatinib in 40 adults with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal was to see if the drug could shrink tumors or stop them from growing. This is a phase II trial, meaning it's still in early testing to check effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.